✦ LIBER ✦

Simeprevir with pegylated interferon alfa 2a or 2b plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-2): a randomised, double-blind, placebo-controlled phase 3 trial

✍ Scribed by Manns, Michael; Marcellin, Patrick; Poordad, Fred; de Araujo, Evaldo Stanislau Affonso; Buti, Maria; Horsmans, Yves; Janczewska, Ewa; Villamil, Federico; Scott, Jane; Peeters, Monika; Lenz, Oliver; Ouwerkerk-Mahadevan, Sivi; De La Rosa, Guy; Kalmeijer, Ronald; Sinha, Rekha; Beumont-Mauviel, Maria

Book ID: 124130055
Publisher: The Lancet
Year: 2014
Tongue: English
Weight: 287 KB
Volume: 384
Category: Article
ISSN: 0140-6736
DOI: 10.1016/S0140-6736(14)60538-9

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Simeprevir with pegylated interferon alf

Simeprevir with pegylated interferon alfa 2a plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-1): a phase 3, randomised, double-blind, placebo-controlled trial

✍ Jacobson, Ira M; Dore, Gregory J; Foster, Graham R; Fried, Michael W; Radu, Moni 📂 Article 📅 2014 🏛 The Lancet 🌐 English ⚖ 284 KB

Boceprevir versus placebo with pegylated

Boceprevir versus placebo with pegylated interferon alfa-2b and ribavirin for treatment of hepatitis C virus genotype 1 in patients with HIV: a randomised, double-blind, controlled phase 2 trial

✍ Sulkowski, Mark; Pol, Stanislas; Mallolas, Josep; Fainboim, Hugo; Cooper, Curtis 📂 Article 📅 2013 🏛 The Lancet 🌐 English ⚖ 333 KB

1416 FALDAPREVIR PLUS PEGYLATED INTERFER

1416 FALDAPREVIR PLUS PEGYLATED INTERFERON ALFA-2A AND RIBAVIRIN IN CHRONIC HCV GENOTYPE-1 TREATMENT-NAÏVE PATIENTS: FINAL RESULTS FROM STARTVERSO1, A RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE III TRIAL

✍ Ferenci, P.; Asselah, T.; Foster, G.R.; Zeuzem, S.; Sarrazin, C.; Moreno, C.; Ou 📂 Article 📅 2013 🏛 Elsevier Science 🌐 English ⚖ 73 KB

Sofosbuvir with pegylated interferon alf

Sofosbuvir with pegylated interferon alfa-2a and ribavirin for treatment-naive patients with hepatitis C genotype-1 infection (ATOMIC): an open-label, randomised, multicentre phase 2 trial

✍ Kowdley, Kris V; Lawitz, Eric; Crespo, Israel; Hassanein, Tarek; Davis, Mitchell 📂 Article 📅 2013 🏛 The Lancet 🌐 English ⚖ 241 KB

Randomized, double-blind, placebo-contro

Randomized, double-blind, placebo-controlled study of peginterferon alfa-2a (40KD) plus ribavirin with or without amantadine in treatment-naïve patients with chronic hepatitis C genotype 1 infection

✍ Peter Ferenci; Elisabeth Formann; Hermann Laferl; Michael Gschwantler; Franz Hac 📂 Article 📅 2006 🏛 Elsevier Science 🌐 English ⚖ 182 KB

Sofosbuvir in combination with peginterf

Sofosbuvir in combination with peginterferon alfa-2a and ribavirin for non-cirrhotic, treatment-naive patients with genotypes 1, 2, and 3 hepatitis C infection: a randomised, double-blind, phase 2 trial

✍ Lawitz, Eric; Lalezari, Jay P; Hassanein, Tarek; Kowdley, Kris V; Poordad, Fred 📂 Article 📅 2013 🏛 The Lancet 🌐 English ⚖ 276 KB